MAGE-3.1 peptide-pulsed autologous PBMC + rhIL-12

This experimental cancer vaccine, developed by the University of Chicago, is a cellular immunotherapy designed for the treatment of metastatic melanoma. The therapy involves the ex vivo pulsing of a patient's own peripheral blood mononuclear cells (PBMCs) with MAGE-3.1 peptides, which are specific epitopes of the melanoma-associated antigen 3 (MAGE-3). These antigen-loaded cells are then reinfused into the patient in combination with recombinant human interleukin-12 (rhIL-12), which serves as a potent proinflammatory cytokine adjuvant. The mechanism of action relies on the PBMCs presenting the MAGE-3 antigen to the endogenous immune system to prime and expand tumor-specific CD8+ cytotoxic T lymphocytes. The addition of IL-12 enhances the Th1-type immune response and promotes the activation and persistence of these T cells, enabling them to target and eliminate melanoma cells expressing the MAGE-3 antigen.

Other names

MAGE-3.1-University of Chicago-metastatic melanomaMAGE3.1-University of Chicago-metastatic melanomaMAGE 3.1-University of Chicago-metastatic melanomaMAGE-3 peptide-pulsed autologous PBMC plus rhIL-12MAGE3 peptide-pulsed autologous PBMC plus rhIL-12MAGE 3 peptide-pulsed autologous PBMC plus rhIL-12MAGE-3.1 peptide vaccineMAGE3.1 peptide vaccineMAGE 3.1 peptide vaccine